<SEC-DOCUMENT>0001193125-17-003040.txt : 20170105
<SEC-HEADER>0001193125-17-003040.hdr.sgml : 20170105
<ACCEPTANCE-DATETIME>20170105164532
ACCESSION NUMBER:		0001193125-17-003040
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170105
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170105
DATE AS OF CHANGE:		20170105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		17511366

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d287874d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): January&nbsp;5, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-21392</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street 28-32, Dublin 2,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ireland</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.02. Results of Operations and Financial Condition. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;5, 2017, Amarin Corporation plc, or the Company, issued a press release providing preliminary unaudited fourth quarter and annual 2016
financial guidance and its financial outlook for 2017. A copy of the Company&#146;s press release is furnished herewith as Exhibit 99.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The
information set forth under Item&nbsp;2.02 and in Exhibit 99.1 is intended to be furnished and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;),
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such filing. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated January&nbsp;5, 2017</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; * </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: January&nbsp;5, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Amarin Corporation plc</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Thero</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">John Thero</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit&nbsp;Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated January&nbsp;5, 2017</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d287874dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g287874imx1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Provides Preliminary 2016 Results and 2017 Outlook </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Unaudited Full-Year 2016 Net Product Revenue Estimated to Modestly Exceed Upper End of $112 to $125 Million Previously Guided Range </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Anticipate Full-Year 2017 Net Product Revenues Between $155 Million and $165 Million; Commercial Operations Positioned to be Cash Flow
Positive for 2017 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEDMINSTER, N.J., and DUBLIN, Ireland, January&nbsp;5, 2017 &#151; Amarin Corporation plc (NASDAQ: AMRN), today provided a business
update, including an update on 2016 revenue guidance and 2017 revenue forecast. Amarin plans to discuss these results and expectations with investors in conjunction with the 35<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Annual J.P.
Morgan Healthcare Conference in San Francisco, California. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>2016 Operational Progress </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Product Revenue:</B> Continued growth in both new and recurring Vascepa prescriptions in Q4 2016 resulted in increased market share and
directly supported record revenue levels for Q4 and full-year 2016. The company estimates full-year 2016 product revenues, on a GAAP basis subject to audit, modestly exceeded $125&nbsp;million, representing growth of more than 50% over reported 2015
net product revenue of $81&nbsp;million. As reported in the past, inventory levels at wholesalers tend to fluctuate based on seasonal factors, prescribing trends and other factors. During 2016, predominantly in Q2, wholesaler inventory levels
increased based on estimated days of inventory on hand. In addition, regional stocking of Vascepa expanded at certain retail pharmacies, likely due to higher volume sales of Vascepa. Amarin estimates that these changes in channel inventory increased
net product revenues by approximately $3 to $6&nbsp;million during 2016 and that without these increases full-year 2016 net product revenues would have been in the upper end of the company&#146;s previously provided guidance of $112 to
$125&nbsp;million. Estimated prescriptions of Vascepa, based on data from Symphony Health Solutions, increased more than 50% in 2016 over 2015 with Vascepa market share for both total prescriptions (TRx) and new prescriptions (NRx) exceeding 20% of
the prescription <FONT STYLE="white-space:nowrap">omega-3</FONT> market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">REDUCE-IT:</FONT> </B>Five
years of the <FONT STYLE="white-space:nowrap">six-year</FONT> estimated duration for this 8,175 patient cardiovascular outcomes study are now complete. Cardiovascular risk, despite <FONT STYLE="white-space:nowrap">LDL-cholesterol</FONT> management
via statin therapy, remains high. <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> is the first multi-national prospective cardiovascular outcomes study ever conducted to evaluate the effect of treating patients who despite statin use have elevated
triglyceride levels with a therapy that significantly lowers triglycerides. <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> is also the first cardiovascular outcomes study to test a high, <FONT STYLE="white-space:nowrap">4-gram</FONT> per day dose
of a pure-EPA <FONT STYLE="white-space:nowrap">omega-3</FONT> product. <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results, assuming success, are intended to support significantly expanded promotion and use of Vascepa to treat <FONT
STYLE="white-space:nowrap">at-risk</FONT> patients to lower the rates of major adverse cardiovascular events. Tens of millions of people in the United States alone have elevated triglycerides. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> is a cardiovascular events driven study
designed to provide 90% power to detect a 15% relative risk reduction between the patient arm treated with Vascepa added to well-controlled statin therapy compared to the patient arm treated with placebo added to well-controlled statin therapy. The
study is designed to be completed upon reaching 1,612 primary cardiovascular events which Amarin estimates will occur near the end of 2017 with results expected to be reported and published in 2018. The study is being conducted under a special
protocol assessment (SPA) agreement with the FDA which was amended and <FONT STYLE="white-space:nowrap">re-affirmed</FONT> with the FDA in 2016 along with finalization of the study&#146;s statistical plan. A
<FONT STYLE="white-space:nowrap">pre-specified</FONT> interim efficacy and safety analysis is scheduled to be conducted by the independent data monitoring committee (DMC) at approximately 80% of the total 1,612 primary cardiovascular events targeted
for completion of the study. Amarin anticipates that onset of 80% of the target events will be reached in the first half of 2017 and that the interim analysis will be conducted before the end of Q3 2017. Consistent with the trial design, Amarin
continues to believe that the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study is most likely to continue to completion of 100% of the target events as the requirements for early stoppage for overwhelming efficacy are high. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet: </B>Amarin ended 2016 with approximately $98&nbsp;million in cash and approximately $20&nbsp;million in net accounts
receivable. The company also has $15.1&nbsp;million of outstanding exchangeable debt which, as previously disclosed, may be put to the company on January&nbsp;19, 2017. The company is positioned to be cash flow positive for 2017 from commercial
operations excluding costs for <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> interest and royalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are very pleased with the progress
Amarin made in 2016 with revenue growth, execution on <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> expense management, increased productivity, lowered product cost and improved gross margins, strengthening of our management team, securing new
chemical entity designation, publication of scientific findings, expanded managed care coverage, international expansion and numerous other advances that individually and collectively position Amarin for continued growth and positive
execution,&#148; commented John F. Thero, president and chief executive officer. &#147;We expect 2017 to be an exciting year for Amarin as we build upon this progress and prepare for results of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT>
study.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>2017 Objectives and Financial Outlook </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin&#146;s core strategy remains unchanged. Our primary objectives are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">Continue to aggressively grow revenues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">Complete the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study on a timely basis while maximizing the likelihood of success; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">Operate in a cost effective, opportunistic manner. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company begins 2017 expecting to achieve the following
results: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>U.S. Product Revenues</B>: Estimated to reach between $155 and $165&nbsp;million with quarterly variability continuing based
on seasonal factors. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>International Expansion</B>: Clarification expected from China FDA regarding the clinical and
regulatory path for Vascepa approval in China. First country approval for marketing Vascepa in the Middle East expected before the end of 2017. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT></B>: As per above, onset of 80% of primary cardiovascular events to occur in the first
half of 2017, the <FONT STYLE="white-space:nowrap">pre-specified</FONT> 80% interim look to be conducted by the DMC before the end of Q3 2017 and targeted final primary cardiovascular event (the
1,612<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> patient with a primary cardiovascular event) to be reached near the end of 2017 with trial results presented and published in 2018. A publication on the clinical design of <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> is anticipated in or before <FONT STYLE="white-space:nowrap">mid-2017.</FONT> Amarin will remain blinded to results of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study until after the study is
stopped and the database is locked at either the second interim analysis or at the final analysis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Spending</B>: Excluding commercial
spending for anticipated expansion post successful <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results, sales, general and administrative expenses, excluding <FONT STYLE="white-space:nowrap">non-cash</FONT> costs, to increase by less than 10%
in 2017 compared with 2016 with the exceptions of increased <FONT STYLE="white-space:nowrap">co-promotion</FONT> fees anticipated to be paid to Kowa associated primarily with anticipated increased revenue growth. Amarin anticipates that R&amp;D
expenses in 2017, excluding <FONT STYLE="white-space:nowrap">non-cash</FONT> costs, will remain relatively consistent with 2016 levels with the majority of such spending devoted to the ongoing <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> trial.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Commercial Preparations for Expansion <FONT STYLE="white-space:nowrap">Post-REDUCE-IT</FONT></B>: Our intention is to significantly
expand promotion of Vascepa upon positive results from <FONT STYLE="white-space:nowrap">REDUCE-IT.</FONT> However, currently we do not intend to significantly expand the size of our sales force until after the
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results are available. Rather, as has been successful in the past two years, we intend to continue to work to improve the productivity of our existing sales team while planning and evaluating how to
best expand Vascepa promotion assuming positive <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results. We anticipate that research and other activities to support such preparations will cost $3 to $5&nbsp;million in
2017.&nbsp;&nbsp;&nbsp;&nbsp;In addition, we anticipate increasing purchases of supply for Vascepa in 2017 both to support anticipated revenue growth in 2017 and to prepare for <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> success. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Cash Flow</B>: Assuming projected revenue growth and spending assumptions per above, we expect Amarin to be cash flow positive from
commercial operations for 2017, excluding <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> interest and royalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin plans to provide further
details regarding its 2016 results and 2017 outlook in connection with the company&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> in late February 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(icosapent ethyl) capsules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(icosapent ethyl) capsules are a single-molecule prescription product consisting of
either 1 gram or 0.5 grams of the <FONT STYLE="white-space:nowrap">omega-3</FONT> acid commonly known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and
<FONT STYLE="white-space:nowrap">complex&nbsp;FDA-regulated</FONT> manufacturing process designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient. Vascepa is known in scientific literature as AMR101.
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">FDA-approved</FONT> Indication and Usage </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for Vascepa </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Vascepa&nbsp;is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to&nbsp;Vascepa&nbsp;or any of its components. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Use with caution in patients with known hypersensitivity to fish and/or shellfish. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most common reported adverse reaction (incidence &gt; 2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). There was no reported adverse reaction &gt; 3% and greater than placebo.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients receiving treatment with&nbsp;Vascepa&nbsp;and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients should be advised to swallow&nbsp;Vascepa&nbsp;capsules whole; not to break open, crush, dissolve, or chew&nbsp;Vascepa. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adverse events and product complaints may be reported by calling <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-855-VASCEPA&nbsp;or&nbsp;the</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FDA&nbsp;at&nbsp;1-800-FDA-1088.</FONT></FONT></FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FULL VASCEPA PRESCRIBING
INFORMATION CAN BE FOUND AT&nbsp;<U>WWW.VASCEPA.COM</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa has been approved for use by the&nbsp;FDA&nbsp;as an adjunct to diet to reduce
triglyceride levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 500 mg/dL) hypertriglyceridemia. Vascepa is under various stages of development for potential use in other indications that have not been approved by
the&nbsp;FDA. Nothing in this press release should be construed as promoting the use of Vascepa in any indication that has not been approved by the&nbsp;FDA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation&nbsp;plc&nbsp;is a
biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.&nbsp;Amarin&#146;s&nbsp;product development program leverages its extensive experience in lipid science and the potential
therapeutic benefits of polyunsaturated fatty acids.&nbsp;Amarin&#146;s&nbsp;clinical program includes a commitment to the ongoing <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes study.&nbsp;Vascepa<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(icosapent <FONT STYLE="white-space:nowrap">ethyl),&nbsp;Amarin&#146;s&nbsp;first&nbsp;FDA-approved</FONT> product, is a <FONT STYLE="white-space:nowrap">highly-pure,&nbsp;EPA-only,</FONT> <FONT
STYLE="white-space:nowrap">omega-3</FONT> fatty acid product available by prescription. For more information about Vascepa, visit <U>www.vascepa.com</U>.&nbsp;For more information about&nbsp;Amarin, visit&nbsp;<U>www.amarincorp.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, including statements about the future commercialization of Vascepa; expectations regarding Vascepa
sales and resulting revenue amounts and company expenses for the fourth quarter of 2016 and for the years ended December&nbsp;31, 2016 and 2017; expectations related to Amarin&#146;s 2017 financial outlook and potentially ending 2017 as cash flow
positive from commercial operations; including expectations for continued event rates, interim data review and results announcements in Amarin&#146;s <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes study; expectations
regarding the continued effect and scope of the court-expanded ability to promote Vascepa and to educate healthcare professionals regarding the efficacy and safety of Vascepa; expectations related to the interim and final outcome of the <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> study and the successful completion of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study; statements regarding quarterly changes and seasonal effects on Vascepa sales; and statements regarding
the potential efficacy, safety and therapeutic benefits of Vascepa, regulatory reviews and approvals of Vascepa internationally and related commercial potential. These forward-looking statements are not promises or guarantees and involve substantial
risks and uncertainties. In particular, as disclosed in its previous filings with the U.S. Securities and Exchange Commission, Amarin&#146;s ability to effectively commercialize Vascepa will depend in part on its ability to continue to effectively
finance its business (including the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study), efforts of third parties, its ability to create market demand for Vascepa through education, marketing and sales activities, to achieve market acceptance
of Vascepa, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale
and promotion of Vascepa and to maintain patent protection for Vascepa. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with
research and development, clinical trials and related regulatory approvals; the risk that historical <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> clinical trial enrollment and randomization rates may not be predictive of future results and
related cost may increase beyond expectations; the risk that Vascepa may not show clinically meaningful effects in <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> or support regulatory approvals for intended uses; the risk associated with pending
litigation; and the risk that patents may not be upheld in patent litigation and applications may not result in issued patents. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can
be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or
circumstances or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of other information about&nbsp;Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and others should note that we communicate with our investors and the public using our company website (<U>www.amarincorp.com</U>), our investor
relations website (<U>http://www.amarincorp.com/investor-splash.html</U>), including but not limited to investor presentations and investor FAQs,&nbsp;Securities and Exchange Commission&nbsp;filings, press releases, public conference calls
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and webcasts.&nbsp;The information that we post on these channels and websites could be deemed to be material information.&nbsp;As a result, we encourage investors, the media, and others
interested in&nbsp;Amarin&nbsp;to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may
include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin&nbsp;Contact Information:</B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><I>Investor Relations:</I><B></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gene Mack</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin
Corporation plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (908) <FONT STYLE="white-space:nowrap">719-1315</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor.relations@amarincorp.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee M. Stern </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trout Group</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (646)
<FONT STYLE="white-space:nowrap">378-2922</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lstern@troutgroup.com</U><I></I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Inquiries: </I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kristie Kuhl </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finn Partners </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (212) <FONT
STYLE="white-space:nowrap">583-2791</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kristie.kuhl@finnpartners.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g287874imx1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287874imx1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M:NA!5@"I'<&OPI_X/*-!L;?Q'\"M22SMDU&ZAU:":Y6,"66-#;%49AR0"S$
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M:?\ ;YTM_M-[X>EBM[?<P&^1\G:@SDG' KX$_P"#B?\ 9(L?CO\ \%H?A;X
M\+P:-X8U;XEZ%:6LMZMJ$BENGN+A$EF" %CA54MUP!UQ7Y8?M%?L\^+_ -E/
MXRZ[X!\=:/<Z%XF\/SF"YMI1\KC^&6-NCQN/F5AP0:]#!Y%@,12C)-J4E>U_
M^ <F)S/%4IM-)I.U[']JFC:S:>(M)M;^PN8+VQO8EGM[B"0213QL-RNK#@J0
M001US5FOYXO^#>?_ (+N/^S5J^E_ [XOZJ[_  ]U"80>'-;NG+'PW,YXMY6/
M_+JS'@_\LR?[I./Z&K>XCNH$EB=)(I%#HZ,&5P1D$$=0?6OELQRZK@ZKI5-N
MC[H]K!XR&(ASQ^:/BG]H/_@X#_9S_9?^)>O^$_&6H^.-.U;PU?/IUX1X4O&M
MFF4X(CFV!'![$'![5P=O_P '27[)U_=1V]GJWCZ_NIFVQV]MX5N))9#Z*HY/
MX5]U_&WX,>&/VA?A?K/@[QCHUCKWA[7+5[:ZM+N%9$964C<,CY6&<AAR" 0:
M_'__ (-./V:?"6C^+?V@/%QTV&\\0>%_$:>&-+O+E%DDLK1?,9MA(RK.0NXC
MJ% KKPU'!3PU2M.,KPMUT=_EH85IXB-:-.+5G?IM;YGZ]_L\_'31OVF/@MX>
M\>>'H-7M=%\36WVNTBU2R>RO$3<RXDA?YD.5/![8HKLE.0**\65FVUL>BKVU
M/SW_ ."A/[/^L>-OVG-3U33OV%/AM\=HKFSM0WB[5_$-A8W=XRQ!?*:.:)GQ
M& %!)P0.*\(NOV7?$D3E&_X)4_""3<.6C\7Z21^?DUZQ_P %*=1^$%I^U-K8
M\8C]M3^V?LMIYK_#HZQ_8" PKM\G[.?*W[0-^!][.>:^<+_Q5^S=;JRR:I_P
M4KMBG+'?K^0/Q!KZ/#*7LH^[T727Z21X]9)S>O7^[_\ (G37W[+VNZ?'O?\
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MVQT\Z)2I/]Z+U:OQ_P##^NWOA76[+4].N9K+4=-N([NUN(FVR02HP9'4]B&
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M?\'7W_!1#P1\98/!WP4\&:U8^(K[PSJ<FL^(;JQF6:WLIA&8HK;>O!D 9V8
M_+\H/.17YL?\$T?V*/&/[>'[7/A3PCX2TVZN[:#4;>\UO40A^S:19QRJTDLK
M]%^4$*.K,0!7CGPX\7VW@+QKI^KWF@Z/XGMK.82RZ7JR2/:7H[I((V1\'U#
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MRY ^7H"<57"J5'GG5:2E:UVO/S%GC]IRQ@KM7/V,_P"#.LX_9)^+7_8VP?\
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MW$9_V*ZN)J3Q$X2H-223ZK_,Y\FFJ,9*II>W<^;O^"M1 _X.4?V5?^N&E_\
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=?LT?\>_BK_L-3?THHK2/P/Y$2^)'IU%%%9FA_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
